^
Association details:
Biomarker:No biomarker
Cancer:Non-Hodgkin’s Lymphoma
Drug:IDP-023 (NK cell stimulant)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Published date:
02/29/2024
Excerpt:
...today announced that the U.S. FDA has granted Fast Track designation for its lead clinical program, IDP-023, for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.